TP53 and B-cell chronic lymphocytic leukemia: The CLL-IPI combines biochemical and clinical parameters (age, clinical staging, serum ß-2 microglobulin) with cellular and genetic features such as TP53 and IGHV mutational status, to provide a more advanced risk stratification (24, 39).